Edition:
United Kingdom

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

60.48USD
14 Dec 2018
Change (% chg)

$-0.52 (-0.85%)
Prev Close
$61.00
Open
$60.41
Day's High
$60.96
Day's Low
$59.85
Volume
253,372
Avg. Vol
323,766
52-wk High
$84.35
52-wk Low
$47.79

Latest Key Developments (Source: Significant Developments)

Seattle Genetics And Takeda Present Positive Data From Phase 3 Echelon-2 Clinical Trial For Adcetris
Tuesday, 4 Dec 2018 

Dec 3 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS AND TAKEDA PRESENT POSITIVE DATA FROM PHASE 3 ECHELON-2 CLINICAL TRIAL FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) IN FRONTLINE TREATMENT OF CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS.SEATTLE GENETICS - RANDOMIZED PHASE 3 CLINICAL TRIAL DEMONSTRATED ADCETRIS PLUS CHEMOTHERAPY RESULTED IN SUPERIOR PROGRESSION-FREE SURVIVAL, OS.  Full Article

Seattle Genetics Q3 Loss Per Share $0.42
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.42.Q3 EARNINGS PER SHARE VIEW $-0.27 -- THOMSON REUTERS I/B/E/S.SEATTLE GENETICS - TOP-LINE DATA FROM ENFORTUMAB VEDOTIN PIVOTAL TRIAL IN METASTATIC UROTHELIAL CANCER EXPECTED IN Q1 OF 2019.QTRLY TOTAL REVENUES $169.4 MILLION VERSUS $135.3 MILLION.  Full Article

Seattle Genetics And Takeda Announce Positive Results From Phase 3 Echelon-2 Clinical Trial Evaluating Adcetris
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS AND TAKEDA ANNOUNCE POSITIVE RESULTS FROM PHASE 3 ECHELON-2 CLINICAL TRIAL EVALUATING ADCETRIS® (BRENTUXIMAB VEDOTIN) IN FRONTLINE CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMA.ADCETRIS IN COMBINATION WITH CHEMOTHERAPY ACHIEVED PRIMARY ENDPOINT.FIRST RANDOMIZED PHASE 3 TRIAL TO SHOW IMPROVEMENT IN OVERALL SURVIVAL IN FRONTLINE PERIPHERAL T-CELL LYMPHOMA.STATISTICALLY SIGNIFICANT IMPROVEMENT ACHIEVED IN ALL KEY SECONDARY ENDPOINTS, INCLUDING OVERALL SURVIVAL IN PHASE 3 TRIAL.INTENDS TO SUBMIT SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR APPROVAL IN NEAR FUTURE.  Full Article

Seattle Genetics Announces Adcetris Approval In Japan
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES ADCETRIS® (BRENTUXIMAB VEDOTIN) APPROVAL IN JAPAN FOR FRONTLINE HODGKIN LYMPHOMA.SEATTLE GENETICS INC - JAPANESE APPROVAL TRIGGERS MILESTONE PAYMENT TO CO OF $10 MILLION.  Full Article

Seattle Genetics, Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Monday, 9 Jul 2018 

July 9 (Reuters) - Astellas Pharma Inc <4503.T>::SEATTLE GENETICS AND ASTELLAS ANNOUNCE PROGRESS IN ENFORTUMAB VEDOTIN UROTHELIAL CANCER CLINICAL DEVELOPMENT PROGRAM.SEATTLE GENETICS INC - ENROLLMENT OF EV-201 PIVOTAL TRIAL COHORT DESIGNED TO SUPPORT POTENTIAL EXPEDITED REGISTRATION PATHWAY IN U.S. COMPLETED.  Full Article

Seattle Genetics Reports Q1 Loss Per Share Of $0.73
Thursday, 26 Apr 2018 

April 26 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.73.Q1 REVENUE $140.6 MILLION VERSUS I/B/E/S VIEW $119.7 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.FOR Q2 OF 2018, SEATTLE GENETICS EXPECTS SALES OF ADCETRIS WILL BE IN RANGE OF $105 MILLION TO $110 MILLION.SEES 2018 RESEARCH AND DEVELOPMENT (RESEARCH AND DEVELOPMENT) $530 MILLION TO $580 MILLION.SEES 2018 SELLING, GENERAL AND ADMINISTRATION (SG&A) $220 MILLION TO $240 MILLION.SEES 2018 NON-CASH COSTS $95 MILLION TO $105 MILLION.ECHELON-2 DATA EXPECTED IN 2018.  Full Article

Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin
Monday, 26 Mar 2018 

March 26 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.SEATTLE GENETICS INC - COS ARE ALSO EVALUATING ENFORTUMAB VEDOTIN IN OTHER SOLID TUMORS, INCLUDING OVARIAN AND NON-SMALL CELL LUNG CARCINOMA.  Full Article

Seattle Genetics Announces FDA Approval Of Adcetris
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) IN COMBINATION WITH CHEMOTHERAPY FOR ADULTS WITH PREVIOUSLY UNTREATED STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA.SEATTLE GENETICS INC - ‍PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE MAY 1, 2018​.SEATTLE GENETICS INC - ‍FDA ALSO GRANTED PRIORITY REVIEW FOR SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ADCETRIS​.  Full Article

Seattle Genetics says FDA grants its Hodgkin Lymphoma treatment priority review status
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Seattle Genetics Inc ::FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) IN FRONTLINE ADVANCED HODGKIN LYMPHOMA.SEATTLE GENETICS INC - FDA GRANTED PRIORITY REVIEW FOR APPLICATION, AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS MAY 1, 2018.  Full Article

TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍CHMP POSITIVE OPINION FOR ADCETRIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​.‍EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINION FOR EXTENSION OF MARKETING AUTHORIZATION OF ADCETRIS​.‍CHMP RECOMMENDED ADCETRIS​ ITS APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍SEATTLE GENETICS AND TAKEDA ARE JOINTLY DEVELOPING ADCETRIS​.  Full Article